Regeneron Pharmaceuticals, Inc. closed at $798.17 on September 22, 2026, marking a 1.69% gain over the prior 24 hours. The advance contributed to a modest 0.56% rise over the trailing seven-day period, suggesting some near-term stabilization in the shares.
Despite the recent uptick, REGN remains down 4.30% over the past 30 days, reflecting broader pressure that has weighed on the stock over a longer horizon. The company's market capitalization stands at $80.8 billion.
The session's move leaves Regeneron holding its position as a large-cap name in the biopharmaceutical sector. The 30-day decline continues to stand in contrast to the more favorable short-term readings recorded over the past week.
